DaVita (DVA) Projected to Post Quarterly Earnings on Thursday

DaVita (NYSE:DVA) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect DaVita to post earnings of $1.75 per share and revenue of $3.22 billion for the quarter. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, analysts expect DaVita to post $11 EPS for the current fiscal year and $13 EPS for the next fiscal year.

DaVita Trading Up 3.0 %

DaVita stock opened at $139.08 on Thursday. DaVita has a 12 month low of $130.96 and a 12 month high of $179.60. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. The business’s fifty day simple moving average is $147.16 and its two-hundred day simple moving average is $155.53. The company has a market capitalization of $11.13 billion, a price-to-earnings ratio of 12.95, a price-to-earnings-growth ratio of 1.07 and a beta of 1.04.

Analyst Ratings Changes

Several brokerages have issued reports on DVA. Barclays lifted their target price on shares of DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price objective on DaVita in a research report on Friday, February 21st. StockNews.com upgraded DaVita from a “hold” rating to a “buy” rating in a research note on Thursday, April 10th. Finally, Cowen reissued a “hold” rating on shares of DaVita in a research report on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, DaVita has a consensus rating of “Hold” and a consensus target price of $166.33.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.